GSR

Glutathione reductase, mitochondrial · P00390 · GSR on Sugi Atlas →

41,944 patent compounds predicted against GSR, 26,164 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL220519	0.42	10/20
Isosorbide Dinitrate (SCHEMBL8253)	0.46	8/20
Hydrochloric Acid (SCHEMBL167869)	0.57	7/20
Hydrochloric Acid (SCHEMBL167870)	0.57	7/20
Isosorbide Mononitrate (SCHEMBL26781)	0.52	7/20
Isosorbide Mononitrate (SCHEMBL26782)	0.52	7/20
SCHEMBL38719	0.50	3/20
SCHEMBL56616	0.49	3/20
Lumiflavin (SCHEMBL193713)	0.42	3/20
Isosorbide (SCHEMBL217707)	0.33	3/20
Lysine (SCHEMBL1645)	1.00	2/20
Lysine (SCHEMBL1646)	1.00	2/20
Lysine (SCHEMBL7343)	1.00	2/20
Ellagic Acid (SCHEMBL20429)	1.00	2/20
Methylene Blue Cation (SCHEMBL127316)	1.00	2/20
Ellagic Acid (SCHEMBL177722)	0.96	2/20
Lysine (SCHEMBL16683)	0.95	2/20
Lysine (SCHEMBL41760)	0.95	2/20
Lysine (SCHEMBL41761)	0.95	2/20
Lysine (SCHEMBL136469)	0.95	2/20

Clinical trials — most relevant to GSR by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Comparative Study of Dietary and Immunological Management of Refractory Epilepsy in Children	PHASE4	UNKNOWN
Cysteine Supplementation in Critically Ill Neonates	PHASE2/PHASE3	UNKNOWN
Antenatal Melatonin Supplementation for Neuroprotection in Fetal Growth Restriction	PHASE3	RECRUITING
N-Acetylcysteine for Neuroprotection in Parkinson's Disease	PHASE1/PHASE2	COMPLETED
Trial of Oral Glutamine on Mitochondrial Function in CKD	PHASE2	COMPLETED
Effect of Melatonin in Patients With Diabetic Peripheral Neuropathy	PHASE2	RECRUITING
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease	PHASE2	COMPLETED
Safety Study of R(+)Pramipexole to Treat Early Alzheimer's Disease	PHASE2	COMPLETED
The Effects of a Glutathione Precursor (FT061452),on Serum and Intracellular Glutathione Levels	PHASE1	COMPLETED
Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease	PHASE1	COMPLETED
GSNOR Phenotyping/GSNO Challenge in Severe Asthma	EARLY_PHASE1	COMPLETED
GWICTIC: NAC Mechanistic Study in Gulf War Veterans	EARLY_PHASE1	RECRUITING
Effect of Sulfur Amino Acid Depletion and Acetaminophen on Plasma Glutatione	nan	COMPLETED
Neurometabolic Profile of Individuals With Primary Mitochondrial Disease	nan	RECRUITING
Mitochondrial Function of Immune Cells in Sepsis	nan	COMPLETED
The Production of Reactive Oxygen Species in Response to Glutathione Supplementation and Acute Exercise	nan	COMPLETED
Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19	nan	COMPLETED
Assessment of the Impact of N-acetylcysteine Supplementation on Physical Performance	nan	COMPLETED
Mitochondrial Dysfunction in Autism Spectrum Disorder	nan	ACTIVE_NOT_RECRUITING
Plasma Cytochrome c as Biomarker of Traumatic Injury and Predictor of Outcome	nan	COMPLETED
The Premedication Properties of Oral Melatonin in Pediatrics Undergoing Therapeutic Cardiac Catheterization	nan	UNKNOWN
Role of USP35 in the Detection of Ferroptosis in Juvenile Autoimmune Hepatitis	nan	NOT_YET_RECRUITING
High Altitude Medical Research Expedition Himlung 2013 - a Study of Human Adaption to Hypoxia	nan	COMPLETED
Mitochondrial Function in Peripheral Arterial Disease	nan	UNKNOWN
Treating Oxidative Stress and the Metabolic Pathology of Autism	nan	COMPLETED
Effects of Melatonin and Massage After Third Molar Surgery	nan	ACTIVE_NOT_RECRUITING
Relationship Between Mitochondrial Dysfunction and Fatique in Cancer Patients Following External Beam Radiation Therapy	nan	COMPLETED
Mucomyst for Hepatitis C	nan	SUSPENDED
Pathogenic Insights and Search for Biomarkers in RFC1-ataxia/CANVAS	nan	RECRUITING
Nicotinamide Levels in Serum, Aqueous Humor, and Tear Film in Glaucoma and Correlations With Mitochondrial Damage-Associated Molecular Patterns (mtDAMPs) and Senescence-Associated Secretory Phenotype (SASP)	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a GSR binder may also engage these)

Protein	Name	Similarity
A2TIL1	—	1.000	A2TIL1 →
P47791	—	0.996	P47791 →
Q9JLT4	—	0.992	Q9JLT4 →
TXNRD2	Thioredoxin reductase 2, mitochondrial	0.991	landscape →
P70619	—	0.991	P70619 →
TXNRD1	Thioredoxin reductase 1, cytoplasmic	0.988	landscape →
Q9VNT5	—	0.986	Q9VNT5 →
O62768	—	0.986	O62768 →
Q9N2I8	—	0.985	Q9N2I8 →
P78965	—	0.985	P78965 →
Q9Z0J5	—	0.985	Q9Z0J5 →
P27456	—	0.985	P27456 →
TXNRD3	Thioredoxin reductase 3	0.984	landscape →
O89049	—	0.983	O89049 →
Q99MD6	—	0.982	Q99MD6 →
P91938	—	0.982	P91938 →
Q43154	—	0.982	Q43154 →
P42770	—	0.982	P42770 →
P28593	—	0.981	P28593 →
P80461	—	0.981	P80461 →
Q5NVA2	—	0.981	Q5NVA2 →
P39050	—	0.981	P39050 →
Q8T137	—	0.980	Q8T137 →
Q9MYY8	—	0.980	Q9MYY8 →
P39051	—	0.979	P39051 →
P48640	—	0.979	P48640 →
P30635	—	0.979	P30635 →
Q84PW3	—	0.978	Q84PW3 →
P48642	—	0.978	P48642 →
Q9LK94	—	0.978	Q9LK94 →